Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Cerity Partners LLC

Cerity Partners LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 171.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 27,429 shares of the biopharmaceutical company’s stock after acquiring an additional 17,316 shares during the quarter. Cerity Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $12,507,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. OFI Invest Asset Management boosted its holdings in Alnylam Pharmaceuticals by 5.8% in the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 22 shares during the last quarter. Meridian Financial Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 28 shares during the period. Evelyn Partners Investment Management LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 11.5% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 30 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Finally, Sowell Financial Services LLC grew its holdings in Alnylam Pharmaceuticals by 6.2% during the third quarter. Sowell Financial Services LLC now owns 654 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 38 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 10,000 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,517,119.43. The trade was a 13.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 37,778 shares of company stock worth $17,096,988 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ALNY shares. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. JPMorgan Chase & Co. lowered their price target on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Jefferies Financial Group reduced their price objective on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $484.21.

Alnylam Pharmaceuticals Trading Down 0.3%

Shares of ALNY opened at $398.29 on Friday. The firm’s 50-day moving average is $425.72 and its two-hundred day moving average is $420.55. The firm has a market capitalization of $52.62 billion, a P/E ratio of 1,659.54 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.